Flatiron Health Presents Three NSCLC Real-World Evidence Studies at WCLC 2026
Event summary
- Flatiron Health will present three research studies at the 2026 World Conference on Lung Cancer (WCLC) focused on non-small cell lung cancer (NSCLC).
- Studies highlight real-world evidence on immunotherapy, durvalumab consolidation, and adjuvant osimertinib in NSCLC treatment.
- Research leverages Flatiron's Panoramic Database to inform precision medicine strategies in oncology.
- Presentations scheduled for September 13–15, 2026, in Seoul, South Korea.
The big picture
Flatiron Health's WCLC 2026 presentations underscore its role in bridging real-world data with precision oncology. The studies come as NSCLC treatment landscapes evolve rapidly, with targeted therapies and immunotherapies reshaping patient outcomes. Flatiron's ability to generate actionable insights from its Panoramic Database positions it as a key player in oncology decision-making, though it must sustain differentiation in an increasingly data-driven healthcare market.
What we're watching
- Data Utilization
- How Flatiron's real-world evidence will influence NSCLC treatment guidelines and regulatory decisions.
- Competitive Positioning
- Whether Flatiron can maintain its leadership in oncology intelligence amid growing competition.
- Clinical Translation
- The pace at which emerging targeted therapies transition from research to standard clinical practice.
Related topics